Saturday, July 26, 2025

CSafe Providing Sustainable Thermal Protection for Vyjuvek Gene Therapy from Krystal Biotech

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Global Medical Device Packaging Market: An Overview

Valued at USD 43.2 billion in 2025, The Medical Device Packaging...

Pharmaceutical Cold Chain Packaging for GLP-1 Drugs launched

Nordic Cold Chain Solutions launches the Nordic Express Pack,...

The success of IPACK-IMA and Pharmintech 2025 marks a turning point in processing & packaging

Concrete innovation, global vision, measurable results. With a 2025 edition...

CSafe, the largest provider of a complete range of active and passive temperature-controlled shipping solutions for the pharmaceutical industry, is honored to announce an innovative program for Krystal Biotech that provides the cold chain solution for Krystal’s Vyjuvek gene therapy.

CSafe’s custom thermal shipper for Krystal maintains -20°C throughout the product journey to help ensure that doses of Vyjuvek reach clinicians and patients safely. In addition to best-in-class Vacuum Insulated Panel (VIP) technology, the customized CSafe CGT Ultra solution features simplified product handling.

The Vyjukek supply chain is further optimized by utilizing CSafe’s Retest & Reuse program. This approach features reusable shippers that maintain the highest level of thermal performance. When customers participate in CSafe’s reuse program, our highly qualified team inspects, cleans and thermally requalifies the insulation and shippers to assure thermal integrity prior to reuse. This fully managed, end-to-end solution reduces unnecessary landfill waste and is an efficient, effective, and environmentally responsible packaging program.

“Cell and gene therapies are a core focus for CSafe, and we’re honored to support Krystal Biotech and their transformative treatment,” said Patrick Schafer, CSafe CEO. “Using innovative engineering concepts, the CSafe team is able to stay at the forefront of both biopharmaceutical innovation and sustainability approaches. We’re pleased to support the most advanced therapies with the most advanced solutions for the sustainable, high-performance cold chain.”

 

Latest stories

Related stories

Global Medical Device Packaging Market: An Overview

Valued at USD 43.2 billion in 2025, The Medical Device Packaging...

Pharmaceutical Cold Chain Packaging for GLP-1 Drugs launched

Nordic Cold Chain Solutions launches the Nordic Express Pack,...

The success of IPACK-IMA and Pharmintech 2025 marks a turning point in processing & packaging

Concrete innovation, global vision, measurable results. With a 2025 edition...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back